TWi Biotechnology, Inc. (TPEX: 6610)
Health Care · Biotechnology · TW
NT$29.00
+6.62% today · +31.8% 1Y
TWi Biotechnology, Inc. (TPEX: 6610) operates in the Biotechnology industry within the Health Care sector. The company is valued at $187.22M and employs 27 people.
Over the last twelve months the share price has gained 31.8%, trading between 12.85 and 40.85.
Tweenvest scores TWi Biotechnology, Inc. across four factors: quality 30/100. Its strongest factor is quality.
6610 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $187.22M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -2.22
- Dividend yield
- —
- Beta (5Y)
- 0.99
- 52-week high
- NT$40.85
- 52-week low
- NT$12.85
- Avg volume (3M)
- —
- Shares outstanding
- 205.58M
- Employees
- 27
- Next earnings
- —
About TWi Biotechnology, Inc.
TWi Biotechnology, Inc. operates as a clinical-stage biopharmaceutical firm, concentrating on the development and sale of medications designed to address innate immunity disorders, primarily within Taiwan. The company's drug pipeline notably includes AC-203, which is currently undergoing Phase 2 clinical trials for various conditions such as epidermolysis bullosa simplex, epidermolysis bullosa, arthritis, gout, and diabetes mellitus. Additionally, AC-1101 is in Phase 1 trials for vitiligo treatment and is advancing through preclinical stages for atopic dermatitis, granuloma annulare, and other uncommon autoimmune skin diseases. TWi Biotechnology has also established a drug development collaboration with Hong Kong Winhealth Pharma Group Co., Limited, targeting the markets of Mainland China, Hong Kong, and Macao. Founded in 2010, the company is headquartered in Taipei, Taiwan.
- ISIN
- TW0006610009
- Founded
- 2010
- Listed since
- Dec 27, 2016
- Exchange
- Taipei Exchange
- Currency
- TWD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $63.06B | €874.20 | +1.16% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $142.94 | +2.92% |
Figures last refreshed Aug 18, 2026.